Baxalta gains Health Canada approval for OBIZUR
Treatment for patients with acquired hemophilia A
19-Oct-2015 -
Baxalta Incorporated announced that Health Canada has approved OBIZUR [Antihemophilic Factor (Recombinant), Porcine Sequence] for the treatment of bleeding episodes in patients with acquired hemophilia A caused by autoantibodies to coagulation Factor VIII (FVIII), a very rare and life-threatening ...
hemophilia A